Abstract: The present invention relates to optionally substituted 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Abstract: The invention provides compositions and methods for screening individuals for the presence of G-protein coupled receptor (GPCR) variants. The compositions and methods are useful for determining clinical outcome of drug therapy or for tailoring drug therapy for the individual based upon the presence or absence of one or more GPCR variants in the subject.
Type:
Grant
Filed:
July 25, 2002
Date of Patent:
March 25, 2008
Assignee:
Acadia Pharmaceuticals, Inc.
Inventors:
David M. Weiner, Mark R. Brann, Ethan S. Burstein, Jakob L. Hansen, Fabrice Piu, Andria Lee
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Application
Filed:
November 27, 2007
Publication date:
March 20, 2008
Applicant:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Kelly, Kristian Koch, Bo-Ragnar Tolf
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Application
Filed:
September 20, 2007
Publication date:
January 10, 2008
Applicant:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Kelly, Kristian Koch, Bo-Ragnar Tolf
Abstract: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Type:
Grant
Filed:
December 23, 2002
Date of Patent:
December 11, 2007
Assignee:
ACADIA Pharmaceuticals Inc.
Inventors:
Niels Skjaerbaek, Kristian Norup Koch, Bo Lennart Mikael Friberg, Bo-Ragnar Tolf
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Grant
Filed:
May 3, 2006
Date of Patent:
November 27, 2007
Assignee:
Acadia Pharmaceuticals, Inc.
Inventors:
Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Grant
Filed:
July 21, 2005
Date of Patent:
November 6, 2007
Assignee:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Grant
Filed:
May 3, 2006
Date of Patent:
September 25, 2007
Assignee:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
Abstract: Disclosed herein are compounds of Formula I as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
Type:
Application
Filed:
December 29, 2006
Publication date:
September 13, 2007
Applicant:
ACADIA Pharmaceuticals Inc.
Inventors:
Ethan Burstein, Anne Knapp, Roger Olsson, Jorgen Eskildsen, Fredrik Ek
Abstract: Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.
Type:
Grant
Filed:
May 16, 2005
Date of Patent:
September 11, 2007
Assignee:
Acadia Pharmaceuticals Inc.
Inventors:
Nathalie Schlienger, Jan Pawlas, Alma Fejzic, Roger Olsson, Birgitte Winther Lund, Fabrizio Badalassi, Rasmus Lewinsky, Mikkel Boas Thygesen
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Type:
Application
Filed:
February 16, 2007
Publication date:
July 5, 2007
Applicant:
ACADIA Pharmaceuticals Inc.
Inventors:
Carl-Magnus Andersson, Bo Lennart Friberg, Niels Skjaerbaek, Tracy Spalding, Allan Uldam
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Type:
Grant
Filed:
July 17, 2003
Date of Patent:
July 3, 2007
Assignee:
Acadia Pharmaceuticals, Inc.
Inventors:
Carl-Magnus A. Anderson, Bo Lennart M. Friberg, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam
Abstract: The present invention relates to 1,3,8-triara-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Grant
Filed:
September 30, 2002
Date of Patent:
August 8, 2006
Assignee:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
Abstract: Described is method for preparing tertiary amines comprising sequential, exhaustive alkylation of a hydroxylamine derivative and cleavage of the O—N bond using the following steps: a) reacting the hydroxylamine derivative with an alkylating agent or with a carbonyl compound to form an oxime intermediate. b) reacting the oxime intermediate with a reducing agent to produce an alkylated derivative c) reacting the alkylated derivative with an alkylating agent or a carbonyl compound in the presence of a reducing agent to produce a dialkylated derivative d) reacting the dialkylated derivative with an alkylating agent to produce a quaternized derivative e) reacting the quaternized derivative with a reagent causing cleavage of the O—N bond to produce a tertiary amine.
Type:
Grant
Filed:
August 3, 2000
Date of Patent:
October 4, 2005
Assignee:
Acadia Pharmaceuticals Inc.
Inventors:
Carl-Magnus A. Andersson, Magnus Gustafsson, Kent R. I. Olsson
Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
Type:
Grant
Filed:
April 3, 2003
Date of Patent:
October 4, 2005
Assignee:
ACADIA Pharmaceuticals Inc.
Inventors:
Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
Abstract: The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
Type:
Grant
Filed:
March 6, 2001
Date of Patent:
November 9, 2004
Assignee:
Acadia Pharmaceuticals, Inc
Inventors:
Carl-Magnus A. Andersson, Glenn Croston, Eva Louise Hansen, Allan Kjaersgaard Uldam
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
Type:
Grant
Filed:
April 7, 2003
Date of Patent:
June 29, 2004
Assignee:
Acadia Pharmaceuticals, Inc.
Inventors:
Carl-Magnus A. Andersson, Glenn Croston, Eva L. Hansen, Allan Kjaersgaard Uldam
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
September 30, 2003
Assignee:
Acadia Pharmaceuticals, Inc.
Inventors:
Carl-Magnus A. Andersson, Bo Lennart M. Friberg, Niels Skjaerbaek, Tracy A. Spalding, Allan K. Uldam